Xiyang Liu

Accelerated Glofitamab as Urgent Bridging to CAR T‐Cell Therapy in High‐Risk Relapsed/Refractory Large B‐Cell Lymphoma

Conventional glofitamab step-up dosing reaches the 30-mg target dose approximately 3 weeks after obinutuzumab. This interval may be difficult to accommodate in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who require disease control within days before cel...